Passage Bio, Inc. filed a Current Report on Form 8-K on November 19, 2026, providing unaudited financial statements of Remix Therapeutics, Inc. and unaudited pro forma combined financial information related to the proposed merger between the two companies.
Key Highlights
- Merger agreement: The Amended and Restated Agreement and Plan of Merger among Passage Bio, Peregrine Merger Sub, Inc., Peregrine Merger Sub II, LLC, and Remix Therapeutics, Inc. was dated September 2, 2026, and further amended on October 5, 2026.
- Stockholder approval: At a Special Meeting held on November 5, 2026, Passage Bio's stockholders approved proposals related to the Merger Agreement.
- Two-step merger structure: Peregrine Merger Sub, Inc. will merge with and into Remix as the First Merger, and Remix will then merge with and into Peregrine Merger Sub II, LLC as the Second Merger, with Merger Sub II surviving as a wholly owned subsidiary of Passage Bio.
- Remix interim financials: Exhibit 99.1 contains unaudited condensed interim financial statements of Remix as of and for the nine months ended September 30, 2026 and 2025, with the information provided by Remix.
- Pro forma financial information: Exhibit 99.2 contains unaudited pro forma combined condensed financial information as of and for the nine months ended September 30, 2026, and the year ended December 31, 2025.
- Pro forma limitations: According to the filing, the unaudited pro forma statements "do not purport to reflect what the actual results of operations or financial condition of the combined company would have been" or be indicative of future results.
Passage Bio Provides Financial Disclosures for Pending Remix Therapeutics Merger
Passage Bio, Inc. (NASDAQ:PASG) filed this Current Report under Item 8.01 (Other Events) to supply financial disclosures tied to its proposed acquisition of Remix Therapeutics, Inc. The filing follows a Special Meeting of Stockholders held on November 5, 2026, at which Passage Bio's stockholders approved proposals related to the Merger Agreement, as the company disclosed.
The merger is structured in two steps. According to the filing, Peregrine Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Passage Bio, will first merge with and into Remix, leaving Remix as the surviving entity and a wholly owned subsidiary of Passage Bio. Immediately after, Remix will merge with and into Peregrine Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Passage Bio, with Merger Sub II surviving. The Merger Agreement was originally dated September 2, 2026, and was further amended on October 5, 2026.
The filing attaches two exhibits to satisfy financial disclosure requirements. Exhibit 99.1 presents unaudited condensed interim financial statements of Remix as of September 30, 2026, and for the nine-month periods ended September 30, 2026 and 2025, with the company noting that "the information in Exhibit 99.1 was provided by Remix." Exhibit 99.2 presents unaudited pro forma combined condensed financial information covering Passage Bio, Remix, and the combined entity, as of and for the nine months ended September 30, 2026, and the year ended December 31, 2025. The filing states these pro forma statements "have been prepared on the basis of certain assumptions and estimates and are subject to other uncertainties." The filing also notes that the document contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and that those statements are subject to risks and uncertainties described in the filing's cautionary language.
What Was Disclosed
Passage Bio filed a Current Report on November 19, 2026, to provide unaudited interim financial statements of Remix Therapeutics and unaudited pro forma combined financials for the proposed two-step merger, following stockholder approval at a Special Meeting on November 5, 2026.



Please wait processing your request...